XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.2
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 27,476,681 20,551,957 24,548,119 18,286,917
Common Stock Options Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 14,556,602 14,693,276 14,180,632 13,978,339
Nonvested Restricted Stock Units Outstanding        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 11,007,405 5,364,447 8,956,361 3,983,640
Nonvested Market-based Restricted Stock Units Outstanding Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 1,912,674 494,234 1,411,126 324,938